TY - JOUR
T1 - The NIMO Scandinavian Study
T2 - A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
AU - Frigstad, S. O.
AU - Haaber, A.
AU - Bajor, A.
AU - Fallingborg, J.
AU - Hammarlund, P.
AU - Bonderup, O. K.
AU - Blom, H.
AU - Rannem, T.
AU - Hellstrom, P. M.
N1 - ISI Document Delivery No.: FK2KJ Times Cited: 0 Cited Reference Count: 31 Frigstad, Svein Oskar Haaber, Anne Bajor, Antal Fallingborg, Jan Hammarlund, Per Bonderup, Ole K. Blom, Hakan Rannem, Terje Hellstrom, Per M. Pharmacosmos A/S, Denmark The authors thank all investigators and study staff for their contribution to the study, as well as BioStata ApS, Denmark, for providing statistical support. This work was supported by Pharmacosmos A/S, Denmark. From Pharmacosmos A/S, Denmark, the authors specially thank Dorte Rytter Nielsen, Malin Winterleijon, and Sylvia Simon for coordinating and supporting the study. Critical language review of the manuscript was carried out by Associate Professor Dominic-Luc Webb, Uppsala University, Sweden. 0 Hindawi ltd London 1687-630x
PY - 2017
Y1 - 2017
N2 - Background. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside. Methods. A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year. Results. Out of 282 patients, 82 had Crohn's disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients. Conclusion. Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction.
AB - Background. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside. Methods. A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year. Results. Out of 282 patients, 82 had Crohn's disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients. Conclusion. Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction.
KW - inflammatory-bowel-disease quality-of-life ibd-associated anemia oral iron ferric carboxymaltose management diagnosis multicenter prevalence recurrence Gastroenterology & Hepatology
U2 - 10.1155/2017/4585164
DO - 10.1155/2017/4585164
M3 - Journal article
SN - 1687-6121
VL - 2017
JO - Gastroenterology Research and Practice
JF - Gastroenterology Research and Practice
M1 - 4585164
ER -